Literature DB >> 15157002

Patient-reported outcomes and their role in the assessment of rheumatoid arthritis.

Deborah P Lubeck1.   

Abstract

Patients with rheumatoid arthritis (RA) face considerable physical, social and emotional disabilities. In this chronic disease, for which a cure is not yet available, improving patients' health-related quality of life (HRQoL) is of the utmost concern, particularly as the use of long-term and potentially toxic therapy increases. Early HRQoL outcome measures in RA focused on physical functioning, but the social and emotional aspects of the disease are now increasingly important. Thus, several generic and RA-specific HRQoL instruments have been developed, but no one tool covers all areas of HRQoL that affect the patient with RA. For this reason, a combination of generic and disease-specific tools is currently recommended for RA clinical trials.

Entities:  

Mesh:

Year:  2004        PMID: 15157002     DOI: 10.2165/00019053-200422001-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  85 in total

1.  Arthritis. The cumulative impact of a common chronic condition.

Authors:  E Yelin
Journal:  Arthritis Rheum       Date:  1992-05

2.  Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response.

Authors:  Mark Kosinski; Sara C Kujawski; Richard Martin; Lee A Wanke; Mary C Buatti; John E Ware; Eleanor M Perfetto
Journal:  Am J Manag Care       Date:  2002-03       Impact factor: 2.229

3.  Measuring disease-specific quality of life in clinical trials.

Authors:  G H Guyatt; C Bombardier; P X Tugwell
Journal:  CMAJ       Date:  1986-04-15       Impact factor: 8.262

Review 4.  Economic and quality-of-life impact of rheumatoid arthritis.

Authors:  J J Doyle
Journal:  Manag Care       Date:  2001-07

5.  Quantitative pain assessment for routine care of rheumatoid arthritis patients, using a pain scale based on activities of daily living and a visual analog pain scale.

Authors:  L F Callahan; R H Brooks; J A Summey; T Pincus
Journal:  Arthritis Rheum       Date:  1987-06

6.  Validity, reliability, and sensitivity to change of a French version of the arthritis impact measurement scales 2 (AIMS2) in patients with rheumatoid arthritis treated with methotrexate.

Authors:  J Pouchot; F Guillemin; J Coste; C Brégeon; J Sany
Journal:  J Rheumatol       Date:  1996-01       Impact factor: 4.666

7.  The assessment and prediction of functional disability in rheumatoid arthritis.

Authors:  F Wolfe; M A Cathey
Journal:  J Rheumatol       Date:  1991-09       Impact factor: 4.666

8.  Measuring population health: a comparison of three generic health status measures.

Authors:  Susan Macran; Helen Weatherly; Paul Kind
Journal:  Med Care       Date:  2003-02       Impact factor: 2.983

Review 9.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

10.  Severity of disability and duration of disease in rheumatoid arthritis.

Authors:  J P Leigh; J F Fries; N Parikh
Journal:  J Rheumatol       Date:  1992-12       Impact factor: 4.666

View more
  43 in total

1.  Articular damage in late rheumatoid arthritis.

Authors:  Emel Eksioglu; Reyhan Tuncay; Eda Gurcay; Ajda Bal; Aytul Cakci
Journal:  Clin Rheumatol       Date:  2006-04-22       Impact factor: 2.980

2.  Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment.

Authors:  Ming-Han Chen; Mei-Hsuan Lee; Hsien-Tzung Liao; Wei-Sheng Chen; Chien-Chih Lai; Chang-Youh Tsai
Journal:  Clin Rheumatol       Date:  2018-01-06       Impact factor: 2.980

3.  Clinically important changes in short form 36 health survey scales for use in rheumatoid arthritis clinical trials: the impact of low responsiveness.

Authors:  Michael M Ward; Lori C Guthrie; Maria I Alba
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-12       Impact factor: 4.794

Review 4.  Pegloticase: in treatment-refractory chronic gout.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

Review 5.  Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Amy S Mudano; Elizabeth Tanjong Ghogomu; Maria E Suarez-Almazor; Rachelle Buchbinder; Lara J Maxwell; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

6.  Improved responsiveness and reduced sample size requirements of PROMIS physical function scales with item response theory.

Authors:  James F Fries; Eswar Krishnan; Matthias Rose; Bharathi Lingala; Bonnie Bruce
Journal:  Arthritis Res Ther       Date:  2011-09-14       Impact factor: 5.156

7.  Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.

Authors:  D van der Heijde; L Klareskog; A Singh; J Tornero; J Melo-Gomes; C Codreanu; R Pedersen; B Freundlich; S Fatenejad
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

8.  Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR).

Authors:  Andrea Rubbert-Roth; Paul P Tak; Cristiano Zerbini; Jean-Luc Tremblay; Luis Carreño; Gillian Armstrong; Neil Collinson; Tim M Shaw
Journal:  Rheumatology (Oxford)       Date:  2010-05-12       Impact factor: 7.580

Review 9.  Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.

Authors:  Jasvinder A Singh; Alomgir Hossain; Elizabeth Tanjong Ghogomu; Amy S Mudano; Lara J Maxwell; Rachelle Buchbinder; Maria Angeles Lopez-Olivo; Maria E Suarez-Almazor; Peter Tugwell; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2017-03-10

Review 10.  Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.

Authors:  Jasvinder A Singh
Journal:  Curr Rheumatol Rep       Date:  2016-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.